{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:47:15Z","timestamp":1791362835218,"version":"4.3.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R01AI140303"],"award-info":[{"award-number":["5R01AI140303"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40262-025-01611-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:19:27Z","timestamp":1770365967000},"page":"479-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct04953715","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-9980","authenticated-orcid":false,"given":"Moataz E.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8280-1375","authenticated-orcid":false,"given":"Abdelrahman","family":"Saqr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-5640","authenticated-orcid":false,"given":"Guillaume","family":"Onyeaghala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-1726","authenticated-orcid":false,"given":"Rory P.","family":"Remmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-0083","authenticated-orcid":false,"given":"Christopher","family":"Staley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6108-280X","authenticated-orcid":false,"given":"Casey R.","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6409-0485","authenticated-orcid":false,"given":"Levi","family":"Teigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-9821","authenticated-orcid":false,"given":"Weihua","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-2288","authenticated-orcid":false,"given":"Rasha","family":"El-Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-0711","authenticated-orcid":false,"given":"William S.","family":"Oetting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-639X","authenticated-orcid":false,"given":"Arthur J.","family":"Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-0430","authenticated-orcid":false,"given":"Ajay K.","family":"Israni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4145-7045","authenticated-orcid":false,"given":"Pamala A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"2 Suppl 1","key":"1611_CR1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ajt.2023.02.004","volume":"23","author":"KL Lentine","year":"2023","unstructured":"Lentine KL, Smith JM, Miller JM, Bradbrook K, Larkin L, Weiss S, et al. OPTN\/SRTR 2021 annual data report: kidney. Am J Transplant. 2023;23(2 Suppl 1):S21-120.","journal-title":"Am J Transplant"},{"issue":"2","key":"1611_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2021;43(2):150\u2013200.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"1611_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/tri.12133","volume":"26","author":"T Vanhove","year":"2013","unstructured":"Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, et al. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transpl Int. 2013;26(8):813\u201321.","journal-title":"Transpl Int"},{"issue":"4","key":"1611_CR4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000190219","volume":"76","author":"Y Vanrenterghem","year":"1997","unstructured":"Vanrenterghem Y. The use of mycophenolate mofetil (Cellcept) in renal transplantation. Nephron. 1997;76(4):392\u20139.","journal-title":"Nephron"},{"issue":"12","key":"1611_CR5","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1124\/dmd.110.034249","volume":"38","author":"N Fujiyama","year":"2010","unstructured":"Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S. Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010;38(12):2210\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"1611_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1124\/dmd.32.8.775","volume":"32","author":"O Bernard","year":"2004","unstructured":"Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32(8):775\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1611_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/dmd.104.001651","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard N, Ratanasavanh D, Pr\u00e9maud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33(1):139\u201346.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1611_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/clinchem\/45.3.419","volume":"45","author":"E Sch\u00fctz","year":"1999","unstructured":"Sch\u00fctz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999;45(3):419\u201322.","journal-title":"Clin Chem"},{"issue":"3","key":"1611_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/00007691-200206000-00011","volume":"24","author":"M Shipkova","year":"2002","unstructured":"Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit. 2002;24(3):390\u20139.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1611_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1600-6143.2005.00779.x","volume":"5","author":"DA Hesselink","year":"2005","unstructured":"Hesselink DA, van Hest RM, Mathot RAA, Bonthuis F, Weimar W, de Bruin RWF, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5(5):987\u201394.","journal-title":"Am J Transplant"},{"issue":"6","key":"1611_CR11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/ki.2013.517","volume":"85","author":"H Colom","year":"2014","unstructured":"Colom H, Lloberas N, Andreu F, Cald\u00e9s A, Torras J, Oppenheimer F, et al. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int. 2014;85(6):1434\u201343.","journal-title":"Kidney Int"},{"issue":"1","key":"1611_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1611_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429\u201355.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1611_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00007691-200002000-00003","volume":"22","author":"LM Shaw","year":"2000","unstructured":"Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22(1):14\u20139.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"1611_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","volume":"28","author":"T van Gelder","year":"2006","unstructured":"van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28(2):145\u201354.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"1611_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.018","volume":"28","author":"A Saqr","year":"2022","unstructured":"Saqr A, Carlson B, Staley C, Rashidi A, Al-Kofahi M, Kaiser T, et al. Reduced enterohepatic recirculation of mycophenolate and lower blood concentrations are associated with the stool bacterial microbiome after hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(7):372.e1-372.e9.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"1611_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/FTD.0000000000001248","volume":"47","author":"ME Mohamed","year":"2025","unstructured":"Mohamed ME, Saqr A, Al-Kofahi M, Onyeaghala G, Remmel RP, Staley C, et al. Limited sampling strategies fail to accurately predict mycophenolic acid area under the curve in kidney transplant recipients and the impact of enterohepatic recirculation. Ther Drug Monit. 2025;47(1):174\u201382.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"1611_CR18","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.transproceed.2004.08.087","volume":"36","author":"S Jirasiritham","year":"2004","unstructured":"Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc. 2004;36(7):2076\u20138.","journal-title":"Transplant Proc"},{"issue":"4","key":"1611_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2125.2006.02626.x","volume":"62","author":"Y Zicheng","year":"2006","unstructured":"Zicheng Y, Peijun Z, Da X, Xianghui W, Hongzhuan C. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol. 2006;62(4):446\u201352.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1611_CR20","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0041-1345(02)03051-8","volume":"34","author":"KPP Braun","year":"2002","unstructured":"Braun KPP, Glander P, Hambach P, B\u00f6hler T, Waiser J, Mai I, et al. Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. Transplant Proc. 2002;34(5):1745\u20137.","journal-title":"Transplant Proc"},{"issue":"8","key":"1611_CR21","first-page":"766","volume":"86","author":"W Julasareekul","year":"2003","unstructured":"Julasareekul W, Eiam-Ong S, Bejraputra O, Seublinvong T. Pharmacokinetics of mycophenolic acid in kidney transplant recipients treated with a low dose (1 gram\/day) of mycophenolate mofetil. J Med Assoc Thai. 2003;86(8):766\u201371.","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"1611_CR22","first-page":"658","volume":"5","author":"F Nazemian","year":"2007","unstructured":"Nazemian F, Mohammadpur AH, Abtahi B, Naghibi M. Pharmacokinetics of mycophenolic acid during the early period after renal transplant. Exp Clin Transplant. 2007;5(2):658\u201363.","journal-title":"Exp Clin Transplant"},{"issue":"9","key":"1611_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1631\/jzus.2005.B0885","volume":"6","author":"XY Lu","year":"2005","unstructured":"Lu XY, Huang HF, Sheng-Tu JZ, Liu J. Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. J Zhejiang Univ Sci B. 2005;6(9):885\u201391.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"6","key":"1611_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2125.2007.02934.x","volume":"64","author":"MD Pescovitz","year":"2007","unstructured":"Pescovitz MD, Vincenti F, Hart M, Melton L, Whelchel J, Mulgaonkar S, et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol. 2007;64(6):758\u201371.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1611_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/clinchem\/47.1.88","volume":"47","author":"M Mourad","year":"2001","unstructured":"Mourad M, Malaise J, Chaib Eddour D, De Meyer M, K\u00f6nig J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47(1):88\u201394.","journal-title":"Clin Chem"},{"issue":"1","key":"1611_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/phar.2480","volume":"41","author":"L Schumacher","year":"2021","unstructured":"Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: a multiorgan perspective. Pharmacotherapy. 2021;41(1):103\u201318.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"1611_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00228-017-2285-4","volume":"73","author":"N Bo\u017eina","year":"2017","unstructured":"Bo\u017eina N, Lali\u0107 Z, Na\u0111-\u0160kegro S, Bori\u0107-Bilu\u0161i\u0107 A, Bo\u017eina T, Ka\u0161telan, et al. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients\u2019 and donors\u2019 ABCC2 gene variants, and their interactions. Eur J Clin Pharmacol. 2017;73(9):1129\u201340.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1611_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bcpt.13743","volume":"131","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang H, Li J, Liu L, Wu C, Fu Q, et al. Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: exploratory analysis of the effects of clinical factors and gene variants. Basic Clin Pharmacol Toxicol. 2022;131(1):60\u201373.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"1611_CR29","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1046\/j.1600-6135.2003.00243.x","volume":"3","author":"MD Pescovitz","year":"2003","unstructured":"Pescovitz MD, Guasch A, Gaston R, Rajagopalan P, Tomlanovich S, Weinstein S, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African\u2013American and Caucasian male and female stable renal allograft recipients. Am J Transplant. 2003;3(12):1581\u20136. https:\/\/doi.org\/10.1046\/j.1600-6135.2003.00243.x.","journal-title":"Am J Transplant"},{"key":"1611_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00908","volume":"9","author":"J Zhang","year":"2018","unstructured":"Zhang J, Sun Z, Zhu Z, Yang J, Kang J, Feng G, et al. Pharmacokinetics of mycophenolate mofetil and development of limited sampling strategy in early kidney transplant recipients. Front Pharmacol. 2018;9:908.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1611_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/0091270005278599","volume":"45","author":"PA Jacobson","year":"2005","unstructured":"Jacobson PA, Green KG, Hering BJ. Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J Clin Pharmacol. 2005;45(8):901\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1611_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.1064","volume":"58","author":"M Okour","year":"2018","unstructured":"Okour M, Jacobson PA, Ahmed MA, Israni AK, Brundage RC. Mycophenolic acid and its metabolites in kidney transplant recipients: a semimechanistic enterohepatic circulation model to improve estimating exposure. J Clin Pharmacol. 2018;58(5):628\u201339.","journal-title":"J Clin Pharmacol"},{"key":"1611_CR33","unstructured":"Food and Drug Administration. CellCept \u00ae (mycophenolate mofetil capsules) (mycophenolate mofetil tablets), CellCept \u00ae Oral Suspension (mycophenolate mofetil for oral suspension), CellCept \u00ae Intravenous (mycophenolate mofetil hydrochloride for injection). Package insert and prescribing. [cited 2024 Sep 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050722s021,050723s019,050758s019,050759s024lbl.pdf."},{"issue":"10","key":"1611_CR34","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/A:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278\u201383.","journal-title":"Pharm Res"},{"issue":"8","key":"1611_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1053\/jlts.2001.26365","volume":"7","author":"LE Schmidt","year":"2001","unstructured":"Schmidt LE, Rasmussen A, N\u00f8rrelykke MR, Poulsen HE, Hansen BA. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transplant. 2001;7(8):739\u201342.","journal-title":"Liver Transplant"},{"issue":"3","key":"1611_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/pgs.10.9","volume":"11","author":"KA Barraclough","year":"2010","unstructured":"Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics. 2010;11(3):369\u201390.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"1611_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001448","volume":"9","author":"OM Drevland","year":"2023","unstructured":"Drevland OM, Robertsen I, Theie Gustavsen M, Kveim HK, Herberg Hovd M, Midtvedt K, et al. Impact of fasting status and circadian variation on the pharmacokinetics of mycophenolate mofetil and the glucuronide metabolite in renal transplant recipients. Transplant Direct. 2023;9(3):e1448. https:\/\/doi.org\/10.1097\/TXD.0000000000001448.","journal-title":"Transplant Direct"},{"issue":"1","key":"1611_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11536640-000000000-00000","volume":"50","author":"CMT Sherwin","year":"2011","unstructured":"Sherwin CMT, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1\u201324.","journal-title":"Clin Pharmacokinet"},{"key":"1611_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122792","volume":"351","author":"C Brossier","year":"2024","unstructured":"Brossier C, Jardou M, Janaszkiewicz A, Firoud D, Petit I, Arnion H, et al. Gut microbiota biotransformation of drug glucuronides leading to gastrointestinal toxicity: therapeutic potential of bacterial \u03b2-glucuronidase inhibition in mycophenolate-induced enteropathy. Life Sci. 2024;351:122792.","journal-title":"Life Sci"},{"issue":"3","key":"1611_CR40","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1053\/j.ajkd.2007.11.013","volume":"51","author":"S Bunnapradist","year":"2008","unstructured":"Bunnapradist S, Neri L, Wong W, Lentine KL, Burroughs TE, Pinsky BW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis. 2008;51(3):478\u201386.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1611_CR41","first-page":"925","volume":"28","author":"RE Bullingham","year":"1996","unstructured":"Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28(2):925\u20139.","journal-title":"Transplant Proc"},{"issue":"2","key":"1611_CR42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1365-2125.2003.01863.x","volume":"56","author":"B Shum","year":"2003","unstructured":"Shum B, Duffull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol. 2003;56(2):188\u201397.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1611_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/FTD.0b013e31818b8244","volume":"30","author":"Y Mino","year":"2008","unstructured":"Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, et al. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. Ther Drug Monit. 2008;30(6):656\u201361.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1611_CR44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0091270009335003","volume":"49","author":"T Naito","year":"2009","unstructured":"Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, et al. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients. J Clin Pharmacol. 2009;49(6):710\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1611_CR45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e3181ae44b9","volume":"31","author":"M Miura","year":"2009","unstructured":"Miura M, Satoh S, Niioka T, Kagaya H, Saito M, Hayakari M, et al. Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. Ther Drug Monit. 2009;31(4):467\u201374.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1611_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1078155220980815","volume":"28","author":"K Uchiyama","year":"2022","unstructured":"Uchiyama K, Saito Y, Takekuma Y, Sugita J, Teshima T, Sugawara M. Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients. J Oncol Pharm Pract. 2022;28(1):31\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"1611_CR47","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cts.13495","volume":"16","author":"KM Tornatore","year":"2023","unstructured":"Tornatore KM, Attwood K, Venuto RC, Murray B. Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: implications for health inequities. Clin Transl Sci. 2023;16(5):861\u201371. https:\/\/doi.org\/10.1111\/cts.13495.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"1611_CR48","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1111\/j.1600-6143.2005.01107.x","volume":"5","author":"D Cattaneo","year":"2005","unstructured":"Cattaneo D, Merlini S, Zenoni S, Baldelli S, Gotti E, Remuzzi G, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5(12):2937\u201344.","journal-title":"Am J Transplant"},{"issue":"5","key":"1611_CR49","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740\u20138.","journal-title":"Gut"},{"issue":"3","key":"1611_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1103","volume":"11","author":"M Simoons","year":"2023","unstructured":"Simoons M, Naipal KAT, de Jong H, den Hoed CM, de Winter BCM, Mulder MB. Oral antibiotics lower mycophenolate mofetil drug exposure, possibly by interfering with the enterohepatic recirculation: a case series. Pharmacol Res Perspect. 2023;11(3):e01103.","journal-title":"Pharmacol Res Perspect"},{"key":"1611_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061734","author":"N Dukaew","year":"2023","unstructured":"Dukaew N, Thongkumkoon P, Sirikaew N, Dissook S, Sakuludomkan W, Tongjai S, et al. Gut microbiota-mediated pharmacokinetic drug\u2013drug interactions between mycophenolic acid and trimethoprim-sulfamethoxazole in humans. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15061734.","journal-title":"Pharmaceutics"},{"issue":"9","key":"1611_CR52","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40262-018-0687-9","volume":"57","author":"JB Woillard","year":"2018","unstructured":"Woillard JB, Debord J, Marquet P. Comment on \u201cPopulation pharmacokinetics of mycophenolic acid: an update.\u201d Clin Pharmacokinet. 2018;57(9):1211\u20133. https:\/\/doi.org\/10.1007\/s40262-018-0687-9.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1611_CR53","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.1365-2125.1996.03636.x","volume":"41","author":"R Bullingham","year":"1996","unstructured":"Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol. 1996;41(6):513\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1611_CR54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40168-025-02142-6","volume":"13","author":"OM Drevland","year":"2025","unstructured":"Drevland OM, de Muinck EJ, Trosvik P, Hammerstad M, Kvitne KE, Midtvedt K, et al. Microbiome-derived reactivation of mycophenolate explains variations in enterohepatic recirculation in kidney transplant recipients. Microbiome. 2025;13(1):169. https:\/\/doi.org\/10.1186\/s40168-025-02142-6.","journal-title":"Microbiome."},{"issue":"2","key":"1611_CR55","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2165\/00003495-199651020-00007","volume":"51","author":"B Fulton","year":"1996","unstructured":"Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51(2):278\u201398.","journal-title":"Drugs"},{"issue":"3","key":"1611_CR56","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2215\/CJN.05440610","volume":"6","author":"BCM De Winter","year":"2011","unstructured":"De Winter BCM, Mathot RAA, Sombogaard F, Vulto AG, Van Gelder T. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol. 2011;6(3):656\u201363.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1611_CR57","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","volume":"86","author":"T Van Gelder","year":"2008","unstructured":"Van Gelder T, Silva HT, De Fijter JW, Budde K, Kuypers D, Tyden G, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86(8):1043\u201351.","journal-title":"Transplantation"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01611-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:02:34Z","timestamp":1772640154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01611-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01611-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are not openly available but can be obtained from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"A central Institutional Review Board approval was obtained (Advarra, Columbia, MD, Pro00039619). The study was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All participants provided written consent before the study commenced.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent, which included consent for publication, was obtained from all participants before the study commenced.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Moataz E. Mohamed, Abdelrahman Saqr, Guillaume Onyeaghala, Rory P. Remmel, Christopher Staley, Casey R. Dorr, Weihua Guan, Rasha El-Rifai; William S. Oetting, Arthur J. Matas, Ajay K. Israni, and Pamala A. Jacobson participated in research design. Moataz E. Mohamed, Abdelrahman Saqr, Guillaume Onyeaghala, Rory P. Remmel, Christopher Staley, Casey R. Dorr, Levi Teigen, Weihua Guan, Duy Vo, Rasha El-Rifa,; William S. Oetting, Arthur J. Matas, Ajay K. Israni, and Pamala A. Jacobson participated in performing research. Moataz E. Mohamed conducted the data analysis. Moataz E. Mohamed, Abdelrahman Saqr, Guillaume Onyeaghala, Rory P. Remmel, Christopher Staley, Casey R. Dorr, Levi Teigen, Weihua Guan, Rasha El-Rifai; William S. Oetting, Arthur J. Matas, Ajay K. Israni, and Pamala A. Jacobson participated in the writing of the paper.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}